Difficulties of Mobilization and Harvesting of Hematopoietic Stem Cells in Heavily Pre-Treated Patients

Abstract

This study presents a new method of combined growth factor mobilization with increased dose (15 μg/kg) of filgrastim and standard mono dose of plerixafor in subjects with multiple myeloma, Hodgkin or non-Hodgkin lymphoma. Efficient mobilization is a key factor in the treatment of this group of patients, because autologous transplantation can be performed in cases in which we succeed to obtain a minimally sufficient number of stem cells. Autologous stem cell transplantation is included in the current standard treatment of multiple myeloma and in the relapsed cases of lymphomas.

New Treatment Methods in Multiple Myeloma

“…We used doses of filgrastim (15 μg/kg/day) combined with 0.24 mg/kg of plerixafor on day +5 or +10 of mobilization, and all included patients obtained a sufficient number of stem cells using this method. 18…”